Jean-François Boileau

Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial

Sara A. Hurvitz, Miguel Martín, W. Fraser Symmans et al. · The Lancet Oncology · 2017 · 529 citations · Full text

Medicine, Oncology, Pharmacology +17

NSABP B-47/NRG Oncology Phase III Randomized Trial Comparing Adjuvant Chemotherapy With or Without Trastuzumab in High-Risk Invasive Breast Cancer Negative for HER2 by FISH and With IHC 1+ or 2+

Louis Fehrenbacher, Reena S. Cecchini, Charles E. Geyer et al. · Journal of Clinical Oncology · 2019 · 420 citations · Full text

Medicine, Oncology, Pharmacology +17

Neoadjuvant Trastuzumab Emtansine and Pertuzumab in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Three-Year Outcomes From the Phase III KRISTINE Study

Sara A. Hurvitz, Miguel Martín, Kyung Hae Jung et al. · Journal of Clinical Oncology · 2019 · 248 citations · Full text

Medicine, Oncology, Pharmacology +17

Universal Genetic Testing for Newly Diagnosed Invasive Breast Cancer

Zoulikha Rezoug, Stephanie Totten, David Szlachtycz et al. · JAMA Network Open · 2024 · 20 citations · Full text

Life Sciences, Genetics, Oncology +17

NRG Oncology/NSABP B-47 menstrual history study: impact of adjuvant chemotherapy with and without trastuzumab

Patricia A. Ganz, Reena S. Cecchini, Louis Fehrenbacher et al. · npj Breast Cancer · 2021 · 15 citations · Full text

Medicine, Gynecology, Oncology +17